← all works
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Gastric Cancer Management and Outcomes
- Field
- Medicine
- Canadian institutions
- Hôpital Notre-Dame
- Funders
- —
- Keywords
- RamucirumabMedicineInternal medicineHazard ratioPlaceboClinical endpointGastroenterologyCancerRandomized controlled trialOncologySurgeryConfidence intervalPathology
- Has abstract in OpenAlex
- no